These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35410614)

  • 1. Assessment of the Effect of Timing of Insulin Glargine Administration (Bedtime versus Morning) on Glycemic Control in Children with Type 1 Diabetes in Cairo, Egypt: A Single Centre Experience.
    Shamma RA; Anwar GM; Musa N; Mira MF; Abdou M
    Curr Diabetes Rev; 2023; 19(4):e110422203403. PubMed ID: 35410614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range.
    Elhabashy SA; Sakr EM; Salah NY
    Eur J Pediatr; 2023 Apr; 182(4):1857-1868. PubMed ID: 36800034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
    Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938
    [No Abstract]   [Full Text] [Related]  

  • 4. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A; Schweitzer MA; Häring HU;
    Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial comparing breakfast and bedtime administration of insulin glargine in children and adolescents with type 1 diabetes.
    Şimşek DG; Yıldız B; Asar G; Darcan S
    J Clin Res Pediatr Endocrinol; 2008; 1(1):15-20. PubMed ID: 21318060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Vogelsang DA; Rizza RA; Smith SA; Isley WL
    Endocr Pract; 2007; 13(3):244-50. PubMed ID: 17599855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility.
    Standl E; Maxeiner S; Raptis S;
    Horm Metab Res; 2006 Mar; 38(3):172-7. PubMed ID: 16673208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
    Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
    Bergenstal RM; Bailey TS; Rodbard D; Ziemen M; Guo H; Muehlen-Bartmer I; Ahmann AJ
    Diabetes Care; 2017 Apr; 40(4):554-560. PubMed ID: 28115474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.
    Hamann A; Matthaei S; Rosak C; Silvestre L;
    Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
    Oriot P; Jérémie W; Buysschaert M
    Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
    Pettus J; Gill J; Paranjape S; Stewart J; Malla S; Edelman S; Bergenstal RM; Bode B
    Diabetes Obes Metab; 2019 Aug; 21(8):1906-1913. PubMed ID: 30993855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
    Kazda CM; Bue-Valleskey JM; Chien J; Zhang Q; Chigutsa E; Landschulz W; Wullenweber P; Haupt A; Dahl D
    Diabetes Care; 2023 May; 46(5):1052-1059. PubMed ID: 36920867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.